Alternatives to Phentermine/Topiramate XR If You Can't Fill Your Prescription

If you've been prescribed Qsymia (phentermine/topiramate extended-release) but can't get it filled at a local REMS-certified pharmacy, you have options. Some alternatives contain the exact same active ingredients in a different form. Others are entirely different medications in the same obesity treatment space. Here's what to discuss with your doctor.

Option 1: Phentermine + Topiramate Prescribed Separately (Same Ingredients, No REMS)

The most common workaround for patients who can't access Qsymia is asking their doctor to write two separate prescriptions — one for generic phentermine and one for generic topiramate. Because the Qsymia REMS program applies only to the fixed-dose combination product, these individual generics are not REMS-restricted and can be filled at any standard pharmacy.

Cost is a major advantage: generic phentermine runs about $10–$30 per month, and generic topiramate costs roughly $10–$20 per month, for a combined total of $15–$50 — far below Qsymia's price even with discounts. The trade-off is that the dosing may differ from Qsymia's formulation, since topiramate ER is unique to the combination product and generic topiramate is immediate-release. Discuss the pharmacokinetic differences with your doctor or pharmacist.

Option 2: Contrave (Naltrexone/Bupropion ER) — Oral, No Controlled Substance

Contrave combines naltrexone (an opioid antagonist) and bupropion (an antidepressant/dopamine reuptake inhibitor) in a once-daily extended-release tablet. Like Qsymia, it's FDA-approved for chronic weight management. Unlike Qsymia, it is not a controlled substance, has no REMS program, and can be filled at any pharmacy. Generic Contrave is available and typically costs $50–$150 per month.

Clinical data show average weight loss of about 5–6% of body weight over one year — less than Qsymia's 9–10% at maximum dose, but meaningful for many patients. Contrave is contraindicated with MAOIs and in patients with uncontrolled hypertension, seizure disorders, or anorexia/bulimia.

Option 3: Wegovy (Semaglutide) — Greatest Weight Loss, Higher Cost

Wegovy is a once-weekly injectable GLP-1 receptor agonist approved for adults and adolescents 12+ with obesity. Clinical trials showed average weight loss of about 12–15% of body weight over 68 weeks — significantly more than Qsymia. It's not a controlled substance and has no REMS. However, cost is the major barrier: Wegovy runs $349–$1,600 per month without insurance, and coverage is inconsistent.

The oral version of Wegovy (semaglutide pill) received FDA approval in December 2025 and offers the same active ingredient without needles — it may be a good alternative for patients who want GLP-1 efficacy with oral convenience. Side effects differ from Qsymia and include nausea, vomiting, and diarrhea rather than dry mouth and tingling.

Option 4: Zepbound (Tirzepatide) — Most Weight Loss in Clinical Trials

Zepbound (tirzepatide) is a once-weekly injectable medication that activates both GLP-1 and GIP receptors. It's FDA-approved for obesity and has shown the most weight loss of any approved medication in clinical trials — an average of 15–20% of body weight. Like Wegovy, it's expensive ($350–$1,600/month cash) and not always covered by insurance. No REMS program. Side effects are similar to other GLP-1s, primarily gastrointestinal.

Option 5: Phentermine Alone (Generic or Brand) — Short-Term, Widely Available

Generic phentermine alone is the appetite-suppressing component of Qsymia. It's FDA-approved for short-term weight loss (up to 12 weeks), widely available at any pharmacy, and extremely affordable — as low as $10–$30 per month. About 740,000 prescriptions are filled monthly in the U.S. It's a Schedule IV controlled substance like Qsymia. Weight loss results are moderate and not as sustained as the combination product.

Option 6: Saxenda (Liraglutide) — Daily GLP-1 Injection

Saxenda (liraglutide) is a daily injectable GLP-1 receptor agonist FDA-approved for adults and adolescents 12+ with obesity. Clinical trials showed about 56% of patients lost at least 5% of body weight at one year. It's generally less effective than Wegovy or Zepbound, but has a longer track record. Cost runs several hundred dollars monthly without insurance.

Option 7: Orlistat (Xenical/Alli) — Over-the-Counter, Different Mechanism

Orlistat works by blocking fat absorption in the gut — a completely different mechanism from Qsymia. Alli (60mg) is available over the counter. Xenical (120mg) is prescription-only. Expected weight loss is 3–5% of body weight over 6–12 months. Side effects are primarily gastrointestinal (oily stools, urgent bowel movements) and are worsened by high-fat meals. No controlled substance status, no REMS.

How to Choose: A Quick Comparison

Want the same ingredients with no REMS? → Ask for separate phentermine + topiramate prescriptions

Want oral, no controlled substance, no REMS? → Contrave (naltrexone/bupropion)

Want maximum weight loss and can manage injections? → Wegovy or Zepbound (GLP-1/GIP injectables)

Want the most affordable option at any pharmacy? → Generic phentermine alone ($10–$30/month)

Talk to Your Doctor Before Switching

Before switching medications, always consult your prescriber. Some alternatives have contraindications that may make them unsuitable for your situation (e.g., Contrave cannot be used in patients with seizure disorders; GLP-1s have different thyroid cancer warnings). Also consider whether you've fully exhausted access options for phentermine/topiramate XR — see our guide to finding it in stock before giving up on your original prescription.